Bioxyne receives first psilocybin order
Medicinal cannabis manufacturer Bioxyne has received its first order of GMP-manufactured psilocybin capsules for investigational use in treatment-resistant depression. The...
News
Here, we share stories about our research, innovations in biotechnology, partnerships, and the people behind our mission to support better health from within. Stay informed, stay inspired, and explore how Bioxyne continues to advance science for a healthier tomorrow.
The fun-guys at Bioxyne chalk up their first psilocybin order
Bioxyne has plenty of ‘shroom to move after first psilocybin sale. A first mover in making psychedelic medications, Bioxyne (ASX:BXN)...
Health Check: Biotech quarterlies serve up sizzling aces amid a few unforced errors
ASX biotechs are serving up champion performances amid the odd fault or two, as reflected in today’s crop of quarterly...
Bioxyne hits record quarterly revenue
Brisbane manufacturer Bioxyne delivered record quarterly revenue of A$17.2 million in Q2 FY26, a 21% increase on Q1 and a...
High Tide, Village Farms, Bioxyne: Cannabis stocks as beneficiaries of Trump’s regulatory shift?
The US government under President Donald Trump has changed the federal classification of cannabis. While cannabis is not being legalized...
Bioxyne 2025: Manufacturing psychedelics for PTSD
Bioxyne CEO and Managing Director Sam Watson talked with Proactive about the company’s major developments across medical psychedelics and cannabis...
President Zelensky Signs Bill Legalizing Medical Cannabis in Ukraine
In February 2024, Ukraine took a historic step. President Volodymyr Zelensky signed into law a bill legalizing the use of...
Psilocybin and depression: what this new meta-analysis tells us
In recent years, psychedelic therapy has gone from fringe curiosity to front-page science. The idea that substances like psilocybin —...